Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs) - Summary
Related guides and help
Related acts and regulations
From Health Canada
Overview
This guidance document provides:
- assistance on the interpretation of the regulatory requirements associated with a DIN
 - guidance to manufacturers on their obligation to accurately report to Health Canada the following notifications for a change of drug status within the required timelines:
    
- Market notification
 - 12 months without sale notification
 - Discontinuation of sale notification
 
 
In this guide
- 1. Introduction
 - 2. Purpose
 - 3. Scope
 - 4. Policy objectives
 - 5. Definitions
 - 6. Guidance for implementation
    
- 6.1 DIN assignment
 - 6.2 Drug statuses and the Drug Product Database
 - 6.3 Market notification
 - 6.4 Twelve months without sale notification - dormant status
 - 6.5 Discontinuation of sale notification
 - 6.6 DIN cancellation
        
- 6.6.1 Cancellation due to safety issue
 - 6.6.2 Cancellation due to failure to provide annual drug notification - C.01.014.6 (2) (a) of the Food and Drug Regulations
 - 6.6.3 Cancellation as product is not a drug - C.01.014.6 (1) (c) of the Food and Drug Regulations
 - 6.6.4 Cancellation due to a transition under the Biocides Regulations
 
 - 6.7 Required activities following the cancellation of a DIN
 - 6.8 Reassignment of a DIN by Health Canada
 - 6.9 Commercial exportation
 - 6.10 Submitting notifications to Health Canada
 - 6.11 Contact us
 
 - Appendix A Template email - Request for DIN reassignment
 
View complete guide
Download PDF (700 KB, 31 pages)
Details and history
Administrative changes date: February 18, 2025
Published: May 3, 2019
Consulted: January 25, 2019
Part of topic: Guidance on legislation
For assistance
Our service hours are Monday to Friday from 8 a.m. to 6 p.m. (local time) and closed statuary holidays.
Contact us by email: